LivaNova PLC (NASDAQ:LIVN – Get Free Report) CFO Alex Shvartsburg sold 2,500 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $90.91, for a total transaction of $227,275.00. Following the sale, the chief financial officer directly owned 42,147 shares of the company’s stock, valued at approximately $3,831,583.77. The trade was a 5.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
LivaNova Stock Performance
NASDAQ:LIVN opened at $91.32 on Monday. LivaNova PLC has a one year low of $52.37 and a one year high of $99.38. The business has a fifty day moving average price of $80.32 and a 200-day moving average price of $74.22. The firm has a market capitalization of $5.03 billion, a price-to-earnings ratio of 30.44 and a beta of 0.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.46 and a quick ratio of 1.22.
LivaNova (NASDAQ:LIVN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.17. The company had revenue of $393.15 million for the quarter, compared to the consensus estimate of $381.13 million. LivaNova had a return on equity of 16.10% and a net margin of 13.01%. LivaNova’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 earnings per share. Sell-side analysts forecast that LivaNova PLC will post 3.76 EPS for the current year.
Hedge Funds Weigh In On LivaNova
Several institutional investors have recently bought and sold shares of LIVN. Jump Financial LLC bought a new stake in shares of LivaNova in the 3rd quarter valued at approximately $2,362,000. Empowered Funds LLC purchased a new position in shares of LivaNova in the 3rd quarter worth approximately $2,215,000. First Trust Advisors LP increased its position in shares of LivaNova by 21.2% during the 3rd quarter. First Trust Advisors LP now owns 4,308 shares of the company’s stock valued at $330,000 after purchasing an additional 754 shares during the last quarter. Voya Investment Management LLC increased its position in shares of LivaNova by 0.3% during the 3rd quarter. Voya Investment Management LLC now owns 67,571 shares of the company’s stock valued at $5,169,000 after purchasing an additional 199 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of LivaNova by 27.8% during the 3rd quarter. Bessemer Group Inc. now owns 520 shares of the company’s stock valued at $40,000 after purchasing an additional 113 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on LIVN. Jefferies Financial Group reaffirmed a “buy” rating on shares of LivaNova in a research note on Wednesday, November 4th. Mizuho set a $115.00 price objective on LivaNova in a research report on Wednesday, November 4th. Barclays boosted their price objective on LivaNova from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, November 9th. Zacks Research lowered shares of LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Raymond James Financial set a $120.00 target price on shares of LivaNova in a report on Wednesday, November 4th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, LivaNova has an average rating of “Moderate Buy” and an average price target of $101.22.
Check Out Our Latest Stock Report on LivaNova
LivaNova Company Profile
LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.
Featured Articles
- Five stocks we like better than LivaNova
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
